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Abstract
Background: Factor H binding protein (fHbp) is an important antigen for vaccines against meningococcal serogroup B
disease. The protein binds human factor H (fH), which enables the bacteria to resist serum bactericidal activity. Little is
known about the vaccine-potential of fHbp for control of meningococcal epidemics in Africa, which typically are caused by
non-group B strains.
Methodology/Principal Findings: We investigated genes encoding fHbp in 106 serogroup A, W-135 and X case isolates
from 17 African countries. We determined complement-mediated bactericidal activity of antisera from mice immunized with
recombinant fHbp vaccines, or a prototype native outer membrane vesicle (NOMV) vaccine from a serogroup B mutant
strain with over-expressed fHbp. Eighty-six of the isolates (81%) had one of four prevalent fHbp sequence variants, ID 4/5
(serogroup A isolates), 9 (W-135), or 74 (X) in variant group 1, or ID 22/23 (W-135) in variant group 2. More than one-third of
serogroup A isolates and two-thirds of W-135 isolates tested had low fHbp expression while all X isolates tested had
intermediate or high expression. Antisera to the recombinant fHbp vaccines were generally bactericidal only against isolates
with fHbp sequence variants that closely matched the respective vaccine ID. Low fHbp expression also contributed to
resistance to anti-fHbp bactericidal activity. In contrast to the recombinant vaccines, the NOMV fHbp ID 1 vaccine elicited
broad anti-fHbp bactericidal activity, and the antibodies had greater ability to inhibit binding of fH to fHbp than antibodies
elicited by the control recombinant fHbp ID 1 vaccine.
Conclusion/Significance: NOMV vaccines from mutants with increased fHbp expression elicit an antibody repertoire with
greater bactericidal activity than recombinant fHbp vaccines. NOMV vaccines are promising for prevention of
meningococcal disease in Africa and could be used to supplement coverage conferred by a serogroup A polysaccharide-
protein conjugate vaccine recently introduced in some sub-Saharan countries.
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Introduction
For more than 100 years devastating epidemics of meningo-
coccal disease have occurred in sub-Saharan Africa [1]. In the
decade 1988 to 1997, more than 700,000 cases and over 100,000
deaths were reported. Public health responses were limited by
scarce resources [2]. Further, the only vaccines available, un-
conjugated (plain) polysaccharides, elicited incomplete and short
duration of protection in young children [3,4], and had a minimal
effect on decreasing transmission of the organism [3,5,6]. Control
of epidemic meningococcal disease in Africa, therefore, remains an
unsolved public health challenge.
Most meningococcal disease in industrialized countries is caused
by strains producing capsular serogroups B, C or Y, whereas most
disease in sub-Saharan Africa is caused by serogroup A strains.
After more than ten years of work [7,8], a promising serogroup A
polysaccharide-protein conjugate vaccine recently was developed
for sub-Saharan Africa [9,10]. As of January 21, 2011, nearly 20
million people had been immunized as part of demonstration
projects in three countries (http://www.path.org/menafrivac/
index.php). While this vaccine has the potential to eliminate
serogroup A epidemics, widespread vaccination may result in
selective pressure for replacement of strains with other capsular
serogroups such as X or W-135, which have caused epidemics in
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[15], there is little evidence of serogroup replacement after
widespread use of monovalent serogroup C meningococcal
conjugate vaccines in Europe [16,17]. Pneumococcal serotype
replacement, in contrast, has been a problem in many countries
where pneumococcal polysaccharide-protein conjugate vaccines
were introduced [18–22].
A number of protein antigens are being developed for
prevention of meningococcal serogroup B disease (Reviewed in
[23,24]). These antigens also are prevalent in meningococcal
strains with other capsular serogroups [7,25,26]. Therefore, the
vaccines have the potential to prevent disease caused by non-
group B strains. One of the most promising of the new protein
vaccine candidates is factor H binding protein (fHbp, which was
previously referred to as GNA1870 [27] or LP2086 [28]).
Recombinant fHbp is part of two vaccines in clinical development
for prevention of serogroup B disease [28–30]. Native outer
membrane vesicle vaccines from meningococcal mutants with
over-expressed fHbp also are under investigation [31–36]. The
fHbp antigen is a surface-exposed lipoprotein that binds
complement fH [37], which down-regulates complement activa-
tion and enhances the ability of the organism to escape
complement-mediated bacteriolysis [37–39]. In immunized mice
and humans, antibodies to recombinant fHbp vaccines elicited
complement-mediated serum bactericidal activity [27,28,30,40–
45], which in humans is the hallmark of protection against
meningococcal disease [46–48]. The present investigation was
undertaken to determine the vaccine-potential of fHbp for control
of meningococcal epidemics in Africa caused by serogroup A, W-
135 and X isolates.
Materials and Methods
Objectives
In a previous study, we characterized fHbp sequence variants in
a small collection of serogroup A, W-135 and X isolates from
patients in sub-Saharan Africa [49]. The objectives of the present
study were to determine fHbp sequence variants in an expanded
panel of case isolates from Africa, to measure levels of fHbp
expression, which in previous studies had been reported to be
important for predicting susceptibility of serogroup B strains to
anti-fHbp bactericidal activity [50], and to investigate the
immunogenicity in mice of recombinant fHbp vaccines represen-
tative of sequence variants prevalent among invasive African
strains. The recombinant vaccine immunogenicity results were
compared to that of a prototype native outer membrane vesicle
vaccine (NOMV) prepared from a serogroup B mutant strain
engineered to over-express fHbp. Our hypothesis was that the
NOMV would elicit broader serum bactericidal antibody
responses against the strains from Africa than the recombinant
fHbp vaccines since in previous studies, mutant NOMV vaccines
with over-expressed fHbp elicited broader bactericidal activity
against serogroup B strains [33–36,51].
Descriptions of procedures
Isolates. The 106 isolates were from 17 countries (Figure 1).
Ninety-eight of the isolates were from patients residing within the
meningitis belt, which included the northern district of Gulu,
Uganda (http://www.who.int/csr/don/2006_03_21/en/index.
html)), and eight isolates were from outside the belt (Figure 1,
four countries in gray with hatches). These eight isolates included
three serogroup X and two serogroup A from 1967 to 1989, and
one serogroup A, X, and W-135 isolate from 2001 to 2006. The
106 isolates were selected from a collection of more than 600 case
isolates from Africa that date back to the early 1970s, at the
WHO Collaborating Centre for Reference and Research on
Meningococci, Norwegian Institute of Public Health. Because
individual epidemics are usually clonal, selection of isolates for
the present study was limited to no more than 10 isolates from
any one epidemic in a restricted geographic area and year. We
also included only serogroup A (N=31), W-135 (N=53) or X
(N=22) isolates since strains with these capsular serogroups were
responsible for nearly all meningococcal epidemics in Africa in
recent decades. Since a promising serogroup A conjugate vaccine
was under development for Africa, we included a dispropor-
tionate number of serogroup W-135 and X isolates to provide
data on the vaccine-potential of fHbp to extend coverage to non-
group A strains. The 32 isolates from Burkina Faso were from a
45-year period, and included 22 serogroup W-135 isolates
between 2001 and 2004, six serogroup A isolates from 1963,
1966, 2003 and 2007, and 4 serogroup X isolates from 1997,
2003, and 2007. For all 106 isolates, the year of isolation, country
of origin, capsular serogroup, multilocus sequence type, fHbp
sequence variant, and PorA variable region (VR) type are
provided in Table S1.
To investigate the effect of fHbp expression on susceptibility of
an isolate to anti-fHbp bactericidal activity we engineered isogenic
mutants from serogroup A, B, and W-135 isolates to have different
levels of fHbp expression. The serogroup A isolate, A3 (also
designated Senegal 1/99), was a naturally low fHbp expresser.
The serogroup W-135 isolate, W13 (also designated Sudan 1/06),
was a naturally intermediate fHbp expresser, while the serogroup
B isolate, H44/76, was a naturally high fHbp expresser (See
results). Generation of the respective engineered isolates was made
through modifications of promoters previously described [51].
Multilocus sequence and porA typing. Isolates were
assigned to a specific sequence type (ST) using multilocus
sequence typing (MLST) as described at (http://pubmlst.org/
neisseria/). Variation in the porA gene was determined by DNA
sequencing [52], using an ABI 3730 DNA analyzer (Applied
Biosystems).
Author Summary
Epidemics of meningococcal meningitis are common in
sub-Saharan Africa. Most are caused by encapsulated
serogroup A strains, which rarely cause disease in
industrialized countries. A serogroup A polysaccharide
protein conjugate vaccine recently was introduced in
some countries in sub-Saharan Africa. The antibodies
induced, however, may allow replacement of serogroup A
strains with serogroup W-135 or X strains, which also cause
epidemics in this region. Protein antigens, such as factor H
binding protein (fHbp), are promising for prevention of
meningococcal serogroup B disease. These proteins also
are present in strains with other capsular serogroups. Here
we report investigation of the potential of fHbp vaccines
for prevention of disease caused by serogroup A, W-135
and X strains from Africa. Four fHbp amino acid sequence
variants accounted for 81% of the 106 African isolates
studied. While there was little cross-protective activity by
antibodies elicited in mice by recombinant fHbp vaccines
from each of the four sequence variants, a prototype
native outer membrane vesicle (NOMV) vaccine from a
mutant with over-expressed fHbp elicited antibodies with
broad protective activity. A NOMV vaccine has the
potential to supplement coverage by the group A
conjugate vaccine and help prevent emergence of disease
caused by non-serogroup A strains.
Meningococcal fHbp Vaccine for Africa
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were PCR-amplified from heat-killed cell samples of the isolates
using A1 and B2 primers previously described [27]. DNA
sequences of the PCR products were determined using the A1
and/or 22 primers [27] (Davis Sequencing LLC, Davis, CA). The
analysis presented included 84 newly described sequences and
fHbp sequences from 22 isolates described in a previous study
[49].
Based on analysis of amino acid sequence variants, fHbp
antigens have been subdivided into two sub-families [28], three
variant groups [27], or six major modular groups [50,53]. For
purposes of vaccine development and serological classification we
used the three antigenic variant groups originally described by
Masignani et al [27], which designated sub-family B as variant
group 1, and sub-divided sub-family A fHbp sequences into
variant groups 2 and 3.
Cloning, expression and purification of recombinant
proteins. Expression plasmids were constructed by PCR
amplification of fHbp genes, which was performed as described
previously [50]. Genes encoding four prevalent fHbp sequence
variants, ID 4, 9 and 74 (variant group 1), and ID 22 (variant
group 2), were cloned into pET21b. C-terminal hexahistidine-
tagged recombinant fHbps were expressed in Escherichia coli
BL21(DE3) (Novagen, Madison, WI, US), and purified as
described elsewhere [40]. Additional control recombinant fHbp
vaccines were prepared using similar methods from fHbp genes
encoding ID 1 (variant 1 group), 77 (variant 2 group) and 28
(variant 3 group).
Mouse antisera. Groups of five-week-old CD-1 female mice
(10 mice per group) were obtained from Charles River
(Wilmington, MD, US). For generation of hyperimmune sera,
the mice were immunized intra-peritoneally (IP) with three doses
of recombinant fHbp ID 4, 9, 74, or 22 vaccines, or the control
fHbp ID 1, 77 or 28 vaccines. Each 100 ml dose contained 20 mg
of recombinant protein mixed with Freund’s complete adjuvant
(FA) (Sigma-Aldrich, St. Louis, MO, US) for the first dose and
Freund’s incomplete adjuvant for doses 2 and 3, which were given
at 2-week intervals. Terminal blood samples were obtained three
weeks after the last dose. The sera from the mice immunized with
the respective fHbp ID vaccines were pooled.
We also investigated the vaccine-potential of a prototype
NOMV vaccine prepared from a mutant of group B strain
H44/76 that had been engineered to over-express fHbp ID 1, as
previously described [36,54]. The phenotype of the parent
wildtype strain was B:15:P1.7,16; fHbp ID 1, ST-32, and LOS
L 3,7,9. Control vaccines consisted of a NOMV vaccine prepared
from a H44/76 mutant in which the gene encoding fHbp had
been inactivated [54], or recombinant fHbp ID 1.
The NOMV vaccines consisted of native outer membrane blebs
that were spontaneously released into the culture supernatant
during growth of the bacteria. In brief, bacteria were grown to
early stationary phase (OD 1.0 to 1.2 after 6 hours of growth);
phenol 0.5% (w/v) was added. After overnight incubation at 4uC
to inactivate the bacteria, the culture was centrifuged for 10
minutes at 7500 x g to pellet the bacteria. NOMVs were harvested
from the culture supernatant by the addition of 390 g/l of
ammonium sulfate. The mixture was left overnight at 4uC and the
precipitate was collected by centrifugation at 7500 x g. The
precipitate was suspended in 40 ml PBS, and the NOMV in the
supernatant was collected by centrifugation at 100,000 x g for
2 hours. The isolated blebs were re-suspended in 3% sucrose, and
stored at – 20uC before use.
Based on Western blot, fHbp was detected in the NOMV
vaccine from the mutant with over-expressed fHbp but not in the
fHbp knockout mutant (Figure S1, Panel A). By Coomassie-stained
SDS-PAGE, the two NOMV vaccines contained similar levels of
the major outer membrane proteins PorA and PorB (Panel B); the
NOMV from the mutant with over-expressed fHbp showed higher
amounts of a band resolving at ,30kD, which in a previously
published study was demonstrated by mass spectrometry to
contain both fHbp and OpcA [34]. Based on silver-stained SDS-
PAGE, the respective lipooligosaccharide profiles of the two
NOMV vaccines were similar (Panel C).
For immunization with the NOMV vaccines, each CD1 mouse
received 1.25 mg of total protein, which was adsorbed with 170 mg
of aluminum hydroxide (2% Alhydrogel). Three injections were
given, each separated by 3 weeks and terminal blood samples were
obtained three weeks after the last dose.
Anti-fHbp antibody ELISA. Serum anti-fHbp antibody
responses were measured to recombinant wild-type fHbp ID 1
as previously described [55]. The concentrations of antibody in the
sera from individual mice were assigned in comparison with
binding of anti-fHbp antibody in a reference serum pool from
mice immunized with the recombinant fHbp ID 1 vaccine. The
reference pool was assigned an arbitrary antibody concentration of
1000 units per ml (U/ml).
Anti-fHbp antibody inhibition of binding of fH to
fHbp. We tested the ability of serum anti-fHbp antibodies to
inhibit binding of human fH to fHbp by ELISA, which was
performed as previously described [55] with the following
modifications. The antigen on the plate was recombinant fHbp
ID 4, which was heterologous to the fHbp ID 1 present in both the
recombinant fHbp and fHbp mutant NOMV vaccines (96%
amino acid identity with ID 1). We also used 5 mg/ml of purified
human fH (Calbiochem, San Diego, CA) in the final reaction
mixture instead of IgG-depleted human serum as the source of fH.
The percent inhibition by different dilutions of the immune mouse
sera was calculated by comparison with the amount of human fH
bound in the absence of the mouse antiserum.
Figure 1. Map of Africa showing the source countries (gray) for
the isolates and the number of isolates from that country.
Countries shown in gray with hatches are from outside the meningitis
belt. Gulu district in northern Uganda is part of the meningitis belt (see
text).
doi:10.1371/journal.pntd.0001302.g001
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activity. Serum bactericidal titers were measured as previously
described using early log-phase bacteria grown for approximately
2 h in Mueller-Hinton broth (BD Biosciences, Franklin Lakes, NJ,
US) supplemented with 0.25% glucose (w/v) and 0.02 mM cytidine
59-monophospho-N-acetylneuraminic acid (Sigma-Aldrich, St,
Louis, MO, US) [50]. The complement source was IgG depleted
human serum, which was prepared as described [55].
fHbp expression. fHbp expression was measured in a subset
of isolates from each capsular serogroup. Selection included
representative isolates from different countries and different years
of isolation that spanned 45 years, and which had genes encoding
one of the four predominate fHbp sequence variants, ID 4/5, 9 or
74 (variant group 1), or ID 23 (variant group 2) (See isolates in
Table S1 with ‘‘secondary isolate designations’’). Expression of
fHbp was measured by a quantitative Western blot, which had a
linear range between 0.1 to 2 mg/ml and was performed as
previously reported [50]. For fHbp sequences in variant group 1,
anti-fHbp mAb JAR 3 was used for detection of fHbp sequence
variants ID 1, 4 or 9, and JAR 5 was used for ID 74 [56]. For fHbp
in variant groups 2 or 3, anti-fHbp mAb JAR 31 was used [44].
fHbp expression by the test strains was reported as percentages of
the amount of fHbp expressed by bacterial cells from the
corresponding reference strains H44/76 or 8047 with high
expression of fHbp variant 1 (ID 1) and 2 (ID 77), respectively.
Flow cytometry. We measured binding of mouse anti-fHbp
mAbs to live meningococcal mutants engineered to have increased
or decreased fHbp to assess the relative amounts of fHbp on the
bacterial surface. The flow cytometry assay was performed as
described previously using a combination of two mouse anti-fHbp
mAbs, JAR 4 and JAR 5 [45], each at a final concentration of
10 mg/mL. Controls in the assay included a mouse mAb, specific
for serogroup A (JW-A1) or B (SEAM 12) polysaccharides [57].
Ethics statement
Vaccine immunogenicity was evaluated in CD 1 mice in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Children’s Hospital &
Research Center at Oakland Institutional Animal Care and Use
Committee. Blood collection was performed under anesthesia, and
all efforts were made to minimize suffering. The human
complement source for measuring serum bactericidal activity
was serum from an adult who participated in a protocol that was
approved by the Children’s Hospital Oakland Institutional Review
Board (IRB). Written informed consent was obtained from the
subject.
Statistical analyses
Antibody concentrations were transformed (Log10). For calcu-
lations of geometric mean antibody concentrations, concentrations
below the limit of the assay were assigned a concentration half of
the lower limit. Two-tailed Student’s t tests were used to compare
the geometric mean antibody concentrations between two
independent groups of mice. All statistical tests were two-tailed;
probability values of less than or equal to 0.05 were considered
statistically significant.
Results
The strains from Africa were derived from a limited
number of clonal complexes and PorA sequence variants
The distributions of the prevalent clonal complexes, fHbp
variant groups, and fHbp sequence variants are shown in Figure 2.
The serogroup A isolates were derived from three clonal
complexes: CC 1 (three isolates from 1963 to 1967 and one from
1989), CC 4 (ten from 1966 to 1990), and CC 5 (three from 1988–
1999, and fourteen from 2003–2007). In contrast, the 53
serogroup W-135 isolates were predominately from CC 11
(N=47 from 1994 to 2007). Among the 22 serogroup X isolates,
four were members of a new CC (designated CC 181 (http://
pubmlst.org/neisseria/). Of the remaining 18 isolates, three from
the 19709s were sequence type (ST) 3687, and 15 from 2006–2007
were ST 5403. These two STs differed by only a single nucleotide
change in one of the seven loci (fumC) and, thus, may represent an
undesignated CC, which accounted for 82% of the serogroup X
isolates.
There also were a limited number of PorA VR types (Figure S2).
Among the serogroup A isolates, P1.20,9 was present overall in 55
percent, and in 89 percent of 18 serogroup A isolates obtained
since 1990. Among the serogroup W-135 isolates, P1.5,2 and
related types such as 5-1,2-2 predominated (98%), and among the
serogroup X isolates, P1.19,26 and related type P1.19,26-4
accounted for 68%. The PorA VR typing results are consistent
with previous studies of strains from sub-Saharan Africa [58,59].
The African strains have four prevalent fHbp amino acid
sequence variants
One hundred percent of the serogroup A isolates, 95% of the X
isolates, and 34% of the W-135 isolates had fHbp in the variant 1
group (Figure 2, middle column). The remaining W-135 isolates
had fHbp variant 2 (58%) or 3 (8%); one serogroup X isolate had
fHbp variant 3.
The distribution of the major fHbp amino acid sequence
variants is shown in Figure 2 (right column). All of the group A
isolates had fHbp sequence variants ID 4 or 5, which differed from
each other by a single amino acid. The most prevalent sequence
variants in the serogroup X isolates were ID 74 (67%) and ID 73
(12%); two of the serogroup X isolates in the category ‘‘other’’ had
fHbp ID 4, which was prevalent among serogroup A isolates. With
only a few exceptions the W-135 isolates were clonal based on
having a common clonal complex (CC 11) and PorA VR type
(P1.5,2, see Figure S2). This clone could be subdivided into
multiple subclones based on genes encoding fHbp ID 9 (variant 1),
22/23 (variant 2, and which differed from each other by one
amino acid), or 349 or 111 (variant 3; included in the category
‘‘other’’, Figure 2). Collectively, four fHbp sequence variants (or
related variants, each differing from the respective prevalent
variant by 1 amino acid) were present in 81% of the 106 isolates.
These were fHbp ID 4/5, 74 or 9 (variant 1 group), or ID 22/23
(variant 2 group). The percent amino acid identities between each
of these sequence variants, and between fHbp sequence variants
ID 1, 28 and 77, which were used as control vaccines, are
summarized in Table 1.
Many of the strains from Africa have low fHbp expression
We determined fHbp expression levels in bacterial cells from 44
isolates (Figure 3) using a quantitative Western blot. Six of the 16
group A isolates tested (Panel A), and nine of the 14 W-135
isolates tested with fHbp in the variant 1 group (Panel B), had low
fHbp expression (defined by #33% of fHbp expressed by the
group B reference strain H44/76, which is a naturally high
expresser of fHbp ID 1 in variant group 1). All but one of seven
group W-135 isolates tested with fHbp in the variant group 2
expressed #33% of the group B reference strain 8047, which is a
naturally high expresser of fHbp ID 77 in variant group 2 (Panel
D). In contrast, all but one of the seven group X isolates tested with
fHbp in variant 1 group had high fHbp expression (.100%
Meningococcal fHbp Vaccine for Africa
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had ,80% of the fHbp expressed by H44/76, which was
considered intermediate.
Low fHbp expression is associated with resistance of
mutants to anti-fHbp bactericidal activity
We prepared isogenic mutants with different levels of fHbp
expression from three isolates: a serogroup B reference strain, and
serogroup A and W-135 African isolates. Figure 4 panels A, B and C
illustrate relative expression of fHbp on the surface of live bacteria as
measured by flow cytometry. Panels D, E and F show the
corresponding fHbp expression measured in solubilized bacterial cells
by a quantitative Western blot [50]. For each set of mutants, there was
a 5- to 10-fold range between lowest and highest fHbp expression.
The wildtype serogroup B reference isolate had naturally high
expression of fHbp ID 1. Sera from mice immunized with each of
the recombinant fHbp ID 1, 4, 9, or 74 (variant 1 group) vaccines
had high bactericidal titers against this strain (Figure 4, Panel G).
As expected, this strain was resistant (titer ,1:10) to the serum
from mice immunized with the recombinant fHbp ID 22 vaccine
(variant group 2). Against the isogenic mutant of H44/76 with
58% fHbp expression by Western blot as that of the wildtype
H44/76 strain, the respective anti-fHbp ID 1, 4, 9, or 74
bactericidal titers were ,10-fold lower than the corresponding
titers measured against the higher fHbp expressing wildtype strain
(Panel G). In contrast, none of these antisera was bactericidal
against the H44/76 mutant with low fHbp expression (10% of the
wildtype isolate). The H44/76 wildtype strain and two fHbp
Figure 2. Distribution of clonal complexes (CC), fHbp variant groups, and fHbp sequence variant IDs. CCs were defined by multilocus
sequence typing (MLST) with designations described at http://pubmlst.org/neisseria/. For serogroup X isolates, ST 3687 and 5403 differed by a single
nucleotide change at one of the seven loci (fumC). For purposes of analyses, these isolates were combined as an undesignated 3687/5403 CC. fHbp
variant groups 1, 2 or 3, as described by Masignani et al [27], and fHbp amino acid sequence variant (peptide) IDs as provided at http://pubmlst.org/
neisseria/. For analyses, respective sequence variants differing by one amino acid were combined (i.e., ID 22/23 includes ID 22 and ID 23).
doi:10.1371/journal.pntd.0001302.g002
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positive control mAb against PorA (Panel G, yellow horizontal
hatched bars). Similar respective results were observed with the
mutants of the serogroup A (A3) and serogroup W-135 isolate
(W13). For example, the W-135 wildtype strain with 45% fHbp
expression relative to that of the reference strain was susceptible to
anti-fHbp bactericidal activity only by the antiserum prepared to
the recombinant fHbp vaccine ID 9 that matched that of the
target isolate (titer .1:1000, Panel I). In contrast, the isogenic
mutant with increased fHbp expression (126% relative to H44/76)
was susceptible to anti-fHbp bactericidal activity by antisera to any
of the recombinant fHbp vaccine sequence variants in variant
group 1. While the data from the mutants do not permit a precise
definition of the level of fHbp expression required for homologous
and cross-reactive anti-recombinant fHbp bactericidal activity,
collectively the results indicated that fHbp expression below 30%
of H44/76 was associated with resistance and, with increasing
fHbp expression, the isolates became more susceptible to anti-
fHbp cross-reactive bactericidal activity.
Wildtype strains from Africa are generally susceptible to
anti-fHbp antibodies elicited by the recombinant fHbp
vaccine that matched the sequence variant of the
vaccine but not to antibodies elicited by mismatched
recombinant fHbp variants
Figure 5 shows the anti-fHbp bactericidal titers of antisera
prepared to the different recombinant fHbp sequence variants in
variant group 1 when measured against wildtype serogroup A, W-
135 and X isolates with fHbp in variant group 1. The isolates were
generally susceptible to anti-fHbp antibodies elicited by the
recombinant fHbp vaccine that matched the sequence variant of
the vaccine (blue bars) but not to antibodies elicited by
mismatched recombinant fHbp variants. The lack of cross-reactive
bactericidal activity was most notable for the anti-fHbp ID 1 and
ID 74 antisera (Panels A and D, respectively). This result was
surprising since these vaccines had 92 to 96% amino acid identity
with the fHbp expressed by the test strains (Table 1). In Figure 5
the order of the isolates from left to right is with increasing fHbp
Table 1. Amino acid identity between prevalent African fHbp
sequence variants, and reference fHbp vaccines.
% AMINO ACID IDENTITY
Variant
Group ID 1** 4/5* 9* 74* 22/23* 77** 28**
1 1 100
1 4 96 100
1 9 94 96 100
1 74 93 92 94 100
2 22 68 68 68 69 100
2 77 71 71 72 73 94 100
3 28 61 59 61 61 88 85 100
Amino acid identity from pair-wise alignments between fHbp sequence
variants.
*fHbp sequence variants found among African isolates (ID 4/5 differed from
each other by one amino acid as did ID 22/23).
**fHbp sequence variants used as control vaccines.
doi:10.1371/journal.pntd.0001302.t001
Figure 3. Expression of fHbp by representative African isolates as measured by a quantitative Western blot. Panel A, serogroup A
isolates with fHbp ID 4 or 5; Panel B, serogroup W-135 isolates with fHbp ID 9; Panel C, serogroup X isolates with fHbp ID 73 or 74; and Panel D,
serogroup W-135 isolates with fHbp ID 22 or 23. Bars in Panels A to C represent mean percentages (ranges) compared with expression of fHbp by the
reference group B strain H44/76, which is a relative high expresser of fHbp ID 1 (variant group 1). Bars in Panel D are expression of fHbp compared
with expression by reference group B strain 8047, which is a relative high expresser of fHbp ID 77 (variant group 2). Isolates with means below 33%
were categorized as low fHbp expressers, and above 100% were defined as high expressers (See text).
doi:10.1371/journal.pntd.0001302.g003
Meningococcal fHbp Vaccine for Africa
www.plosntds.org 6 September 2011 | Volume 5 | Issue 9 | e1302expression (as shown in Figure 2). While there were trends for
increased susceptibility to anti-fHbp bactericidal activity with
increasing fHbp expression (for example, the W-135 isolates and
the respective anti-fHbp ID 9 titers), the relationship is not linear,
being confounded by other variables. The lack of linearity is most
evident with the serogroup A isolates where some of the lowest
fHbp expressers (i.e., A1 and A2) were killed by the anti-fHbp ID 4
antiserum that matched that of the isolates, while some of the
highest expressers (i.e., A13 and A14) were resistant.
Figure 6 shows the anti-fHbp bactericidal titers of antisera
prepared to different recombinant fHbp sequence variants in
variant groups 2 or 3 when measured against wildtype serogroup
W-135 isolates with fHbp ID22/23 in variant group 2. The anti-
fHbp ID 22 antiserum was bactericidal against all of the isolates,
even though nearly all of these isolates were low fHbp expressers.
Although these isolates also were killed by the control mismatched
anti-fHbp ID 77 (variant 2) or fHbp ID 28 (variant 3) antisera (84
to 94 percent amino acid identity with fHbp ID 22/23, Table 1),
the respective titers were 10 to 100-fold lower than those of the
anti-fHbp ID 22 antiserum (compare anti-ID 22 bactericidal titers
in Panel B to those in Panels C and D, Figure 6).
Antibodies to a native outer membrane vesicle vaccine
from a mutant with over-expressed fHbp ID 1 kill African
strains resistant to bactericidal activity of antibodies to
recombinant fHbp ID 1 vaccine
We measured susceptibility of 12 African isolates to bactericidal
activity of an antiserum from mice immunized with a prototype
NOMV vaccine prepared from a mutant of group B strain H44/
76 with over-expressed fHbp ID 1 (Figure 7). As controls, we
tested antisera from mice immunized with an NOMV vaccine
from an isogenic fHbp knock-out mutant (NOMV fHbp KO) or a
recombinant fHbp ID 1 vaccine. Against the wildtype serogroup B
H44/76 strain, which was a high expresser of fHbp ID 1 that
matched the recombinant fHbp vaccine, the bactericidal titers of
the control antisera to the NOMV vaccine from the fHbp knock-
out mutant, or the recombinant fHbp ID 1 vaccine, were both
,1:10,240.
Only one of the 12 heterologous African isolates (X4) was
susceptible to bactericidal activity of the antiserum to the
recombinant fHbp ID 1 vaccine (white bars). In contrast, 11 of
the 12 isolates were killed by the antiserum from mice immunized
Figure 4. Bactericidal activity of anti-fHbp antisera in relation to fHbp expression by mutant strains. Panels A, B and C, binding of anti-
fHbp mAbs JAR 4 and JAR 5 to live bacteria as measured by flow cytometry. Gray, low expression mutant; blue, wildtype expression; magenta,
intermediate expression mutant; orange, over-expressed mutant. Panels D, E, and F, fHbp expression measured by quantitative Western blot. Low,
#33% of expression as compared with H44/76 wildtype strain; ‘‘Intermediate’’, 34 to 99% expression; and ‘‘OE’’ (over-expressed) mutants of A3 or
W13 with 105% and 126%, respectively, of H44/76). Panels G, H and I, bactericidal titers of antisera to recombinant fHbp ID 1 (white bars), 4 (black), 9
(gray, diagonal hatches), or 74 (white, stippled) in variant 1, or ID 22 (gray bars) in variant 2, or anti-PorA, mAbs (yellow bars with horizontal hatches)
to P1.7 (H44/76), or P1.9 (A3) or P1.2 (W13). Serogroup B H44/76 is a reference strain with naturally high expression of fHbp ID 1 (variant 1 group).
Serogroup A isolate, A3, is a naturally low expresser of fHbp ID 5 from Senegal. Serogroup W-135 isolate, W13, is a naturally low expresser of fHbp ID
9 from the Sudan.
doi:10.1371/journal.pntd.0001302.g004
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expressed fHbp ID 1 (orange bars), which included both serogroup
A isolates resistant to bactericidal activity of the antiserum to the
recombinant fHbp ID 4 vaccine that matched that of the isolate
(gray bars). The one W-135 strain, W1, which was not killed by
any of the antisera, was the lowest expresser of fHbp (Figure 3).
The remaining three serogroup W-135 tested and all four
serogroup X isolates were killed by sera from the mice immunized
with the NOMV vaccine from the mutant with over-expressed
fHbp ID 1, but the respective bactericidal titers were lower than
the corresponding titers elicited by the recombinant fHbp vaccine
with a sequence variant that matched that of the strain. With one
exception (X5), the bactericidal titers elicited by the control
NOMV vaccine from the fHbp knockout mutant were negative
(titers ,1:10, gray hatched bars). Although not shown in Figure 7,
when we mixed this antiserum with the antiserum to the
recombinant fHbp ID 1 vaccine, the serum bactericidal titers
remained negative (,1:10, 11 isolates) or unchanged (titer 1:50,
isolate X5). Thus, there was no evidence of cooperative
bactericidal activity between anti-fHbp antibodies elicited by the
recombinant fHbp ID 1 vaccine and antibodies elicited to other
antigens in the NOMV. These results are in contrast to a previous
report of cooperative bactericidal activity observed between
human antibodies to recombinant fHbp ID 1 and Neisserial
Heparin binding antigen, which individually lacked bactericidal
activity [60].
Bactericidal activity induced by the mutant NOMV
vaccine is associated with higher anti-fHbp antibody
responses and greater blocking of binding of fH to fHbp
than that induced by the recombinant fHbp vaccine
By ELISA, the mice immunized with the NOMV vaccine from
the mutant with over-expressed fHbp ID 1 had higher serum anti-
fHbp ID 1 antibody concentrations than mice immunized with the
recombinant fHbp ID 1 vaccine (respective geometric means of
2203 and 746 U/ml, P,0.02, Figure 8, Panel A). By ELISA, the
sera from the mice immunized with the mutant NOMV vaccine
also showed greater inhibition of binding of fH to fHbp ID 4,
which was the sequence variant expressed by serogroup A strains
(Panel B, P,0.05 at each dilution tested). The increased fH
inhibition was not only a result of the higher serum anti-fHbp
concentrations in the mutant NOMV vaccine group, but also
appeared to be from a different anti-fHbp antibody repertoire,
since on average the anti-fHbp antibody concentration required
for inhibition of fH in this group was nearly 4-fold lower than in
Figure 5. Complement-mediated bactericidal activity of serum pools from mice immunized with recombinant fHbps in variant 1
(v.1) group against strains with fHbp v.1. Panel A, anti-fHbp ID 1; Panel B, anti-fHbp ID 4; Panel C, anti-fHbp ID 9; Panel D, anti-fHbp ID 74. Blue
bars highlight responses measured against strains expressing the fHbp sequence variant matching that of the vaccine. Bars represent mean titers 6
ranges for individual isolates as measured in at least two independent assays. The anti-fHbp ID 1 antiserum had a titer of 1:10,240 against a control
group B strain with fHbp ID 1 (H44/76, Figure 4, Panel G).
doi:10.1371/journal.pntd.0001302.g005
Meningococcal fHbp Vaccine for Africa
www.plosntds.org 8 September 2011 | Volume 5 | Issue 9 | e1302the recombinant fHbp vaccine ID 1 group (respective geometric
means of 1.17 vs. 4.04 U/ml, P,0.05, Panel C).
Discussion
In this study, we investigated 106 serogroup A, X and W-135
isolates from Africa to assess the vaccine-potential of fHbp for
prevention of meningococcal epidemics. Our results confirm
previous observations that epidemic serogroup A, W-135 and X
isolates from sub-Saharan Africa are derived from a limited
number of clonal complexes and PorA VR sequence variants
[59,61,62]. With respect to fHbp, 95 percent of the isolates overall
had genes encoding fHbp from variant groups 1 or 2. When we
considered fHbp sequence variants that differed by a single amino
acid to be a single sequence variant, 81 percent of the had one of
four prevalent fHbp amino acid sequence variants: three in variant
1 group and one in variant 2 group.
All of the serogroup A strains obtained over a 45 year period
expressed a nearly invariant fHbp ID 4/5 in variant group 1 group.
In a recent report,fHbp ID 4/5(referred to inthe articleas B16and
B22, respectively) also were prevalent among serogroup A isolates
from South Africa, which were from clonal complexes ST-1 and
ST-5 [26]. In the present study, two of the three serogroup X
isolates from South Africa from the 1970s also had fHbp ID 4
(HF24 and HF78, Table S1) [26]. Further, an identical fHbp
variant was prevalent among recent serogroup B isolates from the
United Kingdom [63], and serogroup B and Y isolates from South
Africa [26]. Collectively, these results illustrate remarkable stability
of this fHbp sequence over time. At the opposite extreme with
respect to fHbp variability were the serogroup W-135 isolates in our
study, which were clonal with respect to sequence type (ST-11) and
PorA (P1.5,2), but expressed fHbp sequence variants from variant
Figure 6. Complement-mediated bactericidal activity of serum
pools from mice immunized with recombinant fHbp ID 1 (v.1),
ID 22 (v.2), ID 77 (v.2) or ID 28 (v.3) vaccines as measured
against serogroup W-135 isolates with fHbp ID 22 or 23. Panel
A. anti-fHbp ID 1 (negative control, v.1 antiserum); Panel B, in blue, anti-
fHbp ID 22 (matched to fHbp sequence variant of test isolates); Panel C,
anti-fHbp ID 77 (mismatched sequence variant in v. 2 group), and Panel
D, anti-fHbp ID 28 (mismatched sequence variant in v.3 group). Bars
represent mean titers 6 ranges for individual isolates as measured in at
least two independent assays.
doi:10.1371/journal.pntd.0001302.g006
Figure 7. Bactericidal activity of serum pools from mice
immunized with recombinant fHbp vaccines, or NOMV vac-
cines prepared from mutants of group B strain H44/76 with
over-expressed or inactivated fHbp ID 1. White bars, recombinant
fHbp ID 1; gray bars, recombinant fHbp ID vaccine that matched that of
the test isolates (ID 4, serogroup A; ID 9, serogroup W-135; and ID 74,
serogroup X); orange bars, NOMV vaccine from a mutant of H44/76 with
over-expressed fHbp ID1; gray bars with hatches, NOMV vaccine from a
mutant of H44/76 with fHbp knocked-out. Titers are means 6 ranges of
serum dilutions that gave 50% decreases in CFU/ml after one hr
incubation with human complement measured in at least two assays.
The dose of recombinant fHbp vaccines was 20 mg, which was
administered with Freund’s complete for dose 1 and incomplete
adjuvant for doses 2 and 3. The dose of the NOMV vaccines was 1.25 mg
of total protein adsorbed with 170 mg of aluminum hydroxide.
doi:10.1371/journal.pntd.0001302.g007
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sequence variants, ID 9 (variant group 1) and ID 22 (variant group
2) also were prevalent among the recent ST-11 W-135 isolates from
South Africa (referred to as B45 and A10, respectively) [26]).
Therefore, with certain clones, such as ST-11, there is the potential
for recombination at the fHbp gene locus, which can result in rapid
changes in the fHbp antigenic variant group.
Several previous studies reported broad serum bactericidal
activity against serogroup B strains by vaccination with recombi-
nant fHbp antigens from the respective variant group [64] or sub-
family [30]. In the present study, however, we found limited cross-
reactive serum bactericidal activity in mice immunized with
recombinant fHbp vaccines when measured against serogroup A,
W-135 or X isolates that did not match the amino acid sequence of
vaccine antigen. For the serogroup A and W-135 isolates, low
fHbp expression appeared to contribute to resistance to anti-fHbp
bactericidal activity. When fHbp is sparsely-exposed on the
bacterial surface, the ability of two IgG anti-fHbp antibodies to
bind to appropriately space epitopes, engage C1q and activate
classical complement pathway bacteriolysis may be limited [45].
Our data from isogenic mutant strains with different levels of fHbp
expression directly demonstrated that by increasing fHbp
expression, a resistant wildtype serogroup A or serogroup W-135
isolate became more susceptible to anti-fHbp bactericidal activity
(Figure 4). Conversely, by decreasing fHbp expression, a
susceptible wildtype serogroup B strain became resistant. Among
the serogroup X wildtype isolates, however, low expression was
not a factor for resistance to bactericidal activity since with one
exception these isolates were high fHbp expressers. Low
expression also did not appear to explain resistance of two of the
wildtype serogroup A isolates resistant to bactericidal activity by
antibodies to all of the recombinant fHbp sequence variant
vaccines, including the fHbp ID 4 vaccine that matched fHbp in
the isolates. These two isolates were killed by control antibodies to
the serogroup A capsule and PorA, and by antibodies elicited in
mice by the NOMV vaccine from the mutant with increased
expression of fHbp ID 1. Further studies are needed to define the
basis for resistance of these isolates to bactericidal activity by
serum antibodies to the recombinant fHbp vaccines.
The lack of broad cross-reactive bactericidal antibody activity to
the African isolates in sera from mice immunized with different
recombinant fHbp sequence variants was consistent with recent
data from two clinical trials in the UK showing limited breadth of
serum bactericidal responses after immunization of infants and
toddlers with a multicomponent vaccine containing recombinant
fHbp ID 1 [42,43]. In these trials, broader bactericidal antibody
responses were observed when the recombinant proteins were
combined with a detergent-treated outer membrane vesicle
vaccine, which elicited protective antibodies against PorA and
which also had an adjuvant effect that augmented the serum
antibody responses to the recombinant proteins.
In previous studies, NOMV vaccines from mutants with over-
expressed fHbp elicited broad serum bactericidal antibody
responses in mice against genetically diverse serogroup B strains
[35,36,51,54]. Broad serum bactericidal responses against sero-
group B strains also were recently described in an infant non-
human primate model [33]. In the present study, mice immunized
with an NOMV vaccine from a group B mutant with over-
expressed fHbp ID 1 developed serum bactericidal activity against
all but one of the isolates tested from Africa. In contrast, all but
one of the isolates were resistant to the antiserum to the
recombinant fHbp ID 1 vaccine. For the NOMV vaccines, each
mouse received 1.25 mg of total protein, which was adsorbed with
170 mg of aluminum hydroxide. For the recombinant protein
vaccines, the mice were immunized with 20 mg of recombinant
protein mixed with Freund’s complete adjuvant for the first dose
and Freund’s incomplete adjuvant for doses 2 and 3. If anything,
the broad serum bactericidal titers elicited by the lower dose of
NOMV vaccine given with the aluminum adjuvant, which is
suitable for use in humans, underscores the greater vaccine
potential of this approach to elicit broad protective immunity. At
least three factors appeared to contribute to the enhanced serum
bactericidal antibody responses to the NOMV vaccine with
Figure 8. Serum anti-fHbp antibody responses to vaccination
as measured by ELISA. Mice were immunized with a recombinant
fHbp ID 1 vaccine (filled triangles), or a NOMV vaccine prepared from a
mutant of group B strain H44/76 with over-expressed (OE) fHbp ID 1
(open circles), or from a fHbp knock-out (KO) mutant (filled circles).
Panel A. Serum anti-fHbp ID 1 antibody concentrations in arbitrary units
per ml. NOMV OE vaccine group had a higher geometric mean
concentration (horizontal line) than mice immunized with the
recombinant fHbp vaccine (p=0.02). Panel B. Serum anti-fHbp
inhibition of binding of fH to fHbp ID 4. At all dilutions tested, the
mean percent inhibition of the group given the NOMV vaccine from the
mutant with over-expressed fHbp was higher than the recombinant
fHbp vaccine group (p,0.05). Panel C. Serum anti-fHbp ID 1 antibody
concentrations for 50% inhibition of binding of fH to fHbp ID 4. The
geometric mean was lower for the NOMV OE fHbp group than the
recombinant fHbp vaccine group (p,0.05).
doi:10.1371/journal.pntd.0001302.g008
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which in a recent study was shown to be required for broad serum
anti-fHbp bactericidal responses [34]. Second, was the presence of
natural adjuvants in the NOMV such as lipooligosaccharide or
PorB [65]. Third, was the possible effect of fHbp antigen
presentation in the NOMV on anti-fHbp antibody repertoire as
evidenced by greater ability of the anti-fHbp antibodies to inhibit
of binding of fH to fHbp than anti-fHbp antibodies elicited by the
recombinant fHbp ID 1 vaccine (Figure 8). Greater inhibition of
binding of fH to the surface of N. meningitidis also would be
expected to decrease down-regulation of complement activation
by fH, and enhance susceptibility of the organism to bactericidal
activity [37,38].
In summary, the present data from studies in mice immunized
with a prototype NOMV vaccine with increased fHbp expression
suggest that this vaccine approach could supplement coverage
conferred by the serogroup A polysaccharide conjugate vaccine
recently introduced in Africa, and extend coverage against strains
with other serogroups. An important question, however, is
whether a mutant NOMV vaccine that requires several doses
for protection is likely to be practical in a resource poor region
such as Africa as compared with conjugate vaccines against
serogoups X and W-135. In older children and adults, a single
dose of a meningococcal polysaccharide conjugate vaccine can
elicit protective serum antibodies. Protection, however, elicited by
conjugate vaccines is serogroup specific whereas NOMV vaccines
with over-expressed fHbp elicit protective antibodies against
strains with different serogroup capsules. Also, in infants
immunized with a conjugate vaccine, more than one primary
dose usually is necessary for protection [66], and protective serum
antibodies last less than a year or two [67,68]. Thus, periodic
boosting with a conjugate vaccine is required to maintain
immunity [68,69]. Defining an optimal NOMV vaccine schedule
will require studies in humans. That multiple NOMV doses may
be needed to elicit protective antibodies, however, is not
necessarily different from the requirements for eliciting and
maintaining protection by meningococcal conjugate vaccines in
infants and children.
Limitations of the study
There are several important limitations to the present study.
First, we investigated only 106 case isolates. Although these isolates
were from 17 countries, 30 percent were from Burkina Faso.
Africa is a large and diverse continent with a complex ecology
affecting meningococcal transmission and disease. Development of
a mutant NOMV fHbp-based vaccine for sub-Saharan Africa will
require ongoing surveillance of meningococcal strains to assure
that the vaccine antigens match those of the prevalent strains.
Second, for investigation of anti-fHbp antibody activity elicited by
the recombinant fHbp vaccines, we prepared hyperimmune
antiserum pools in mice immunized with the vaccines given with
Freunds complete and incomplete adjuvant. This adjuvant is
unsuitable for humans and the high anti-fHbp titers in the
hyperimmune mouse serum pools are unlikely to be achieved in
humans. The poor cross-reactive bactericidal activity of these
mouse antisera is, therefore, likely to be even lower in humans
immunized with recombinant vaccines given with aluminum
adjuvants. The broad serum bactericidal antibody responses to the
mutant fHbp NOMV vaccine, however, were in mice given the
vaccine with aluminum hydroxide.
A third limitation was that while the data from the isogenic
mutants with different levels of fHbp showed a clear relationship
between fHbp expression levels and susceptibility to anti-fHbp
bactericidal activity, the relatively small number of wild type
strains tested, and the presence of potential confounders such as
capsular serogroup [70], LOS [71,72] or alternative fH binding
ligands [73], did not provide sufficient statistical power for a
formal analysis of the relationship between fHbp expression and
anti-fHbp bactericidal activity.
A fourth limitation of the present study is that we used a
prototype NOMV vaccine from a mutant group B strain with
over-expressed fHbp ID 1. We chose this vaccine since it had
worked well in previous studies of group B strains, and an
NOMV vaccine from a similar mutant African strain was not yet
available. Neither the PorA VR type of the group B vaccine strain
nor the fHbp sequence variant was present among the African
isolates. We would anticipate that even higher serum bactericidal
antibody responses would be elicited by NOMV vaccines
prepared from mutant African isolates where the antigens in
the vaccine would be matches to the Africa strains. Finally,
although the serum bactericidal titers of the control mice
immunized with the NOMV from the fHbp knockout were
negative, we had insufficient sera from mice immunized with the
NOMV vaccine from the mutant with over-expressed fHbp to
prove that the bactericidal antibodies were directed against fHbp.
In several previous studies however, we demonstrated that
bactericidal activity against serogroup B strains was greatly or
completely diminished after depletion of anti-fHbp antibodies by
solid phase adsorption [34,36,51].
Supporting Information
Figure S1 Characterization of NOMV vaccines. Panel A.
Expression of fHbp as measured by Western-blot with anti-fHbp
mAb JAR 3. Lane 1, rfHbp ID 1, purified His-tagged protein
expressed in E. coli; Lane 2, NOMV from H44/76 fHbp KO
mutant; Lane 3, NOMV from mutant with over-expressed fHbp
ID 1; Lane 4, NOMV from wildtype H44/76 strain. Panel B.
SDS-PAGE and Coomassie blue stain of NOMV vaccines. M,
Molecular mass markers; Lane 2, fHbp knock-out mutant; Lane 3,
Mutant with over-expressed fHbp. The NOMV from the fHbp
over-expressed mutant showed higher amounts of a band resolving
at ,30kD. In parallel experiments the band resolving in this
portion of the gel contained fHbp and OpcA. Panel C. Silver
stained SDS-PAGE of LOS in NOMV vaccines from fHbp KO
mutant (Lane 2) or fHbp over-expressed mutant (Lane 3).
Amounts of vesicles loaded in each lane were standardized based
on total protein content.
(TIF)
Figure S2 Distribution of PorA variable region (VR)
types among African isolates. PorA VR type designations
were made as described at http://pubmlst.org/neisseria/. Among
the serogroup A isolates, P1.20,9 was present overall in 55%, and
in 89% of 18 serogroup A isolates obtained since 1990. Among the
serogroup W- 135 isolates, P1.5,2 and related types such as 5-1,2-2
predominated (98%), and among the serogroup X isolates,
P1.19,26 and a related type P1.19,26-4 accounted for 68%. These
results are consistent with previous studies of strains from sub-
Saharan Africa [58,59].
(TIF)
Table S1 Characteristic of meningococcal strain panel.
*Designation used in labels of figures, table and text of paper.
{UA, undesignated. Note ST 3687 and ST 5403 differed by only a
single nucleotide change in one of the seven loci (fumC) and, thus,
may represent a new CC. Novartis variant groups as described by
Masignani et al [27]; Pfizer subfamilies as described by Fletcher et
al [28]; Modular groups as described by Beernink & Granoff [53]
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